Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)

NCT02120027 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT02120027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Lead sponsor
Menarini Group
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2014
Completion date
November 30, 2015
Enrollment
558 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea